Success Metrics

Clinical Success Rate
88.2%

Based on 15 completed trials

Completion Rate
88%(15/17)
Active Trials
2(9%)
Results Posted
73%(11 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_1
4
18%
Ph not_applicable
3
14%
Ph phase_2
11
50%
Ph early_phase_1
2
9%
Ph phase_4
2
9%

Phase Distribution

6

Early Stage

11

Mid Stage

2

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
2(9.1%)
Phase 1Safety & dosage
4(18.2%)
Phase 2Efficacy & side effects
11(50.0%)
Phase 4Post-market surveillance
2(9.1%)
N/ANon-phased studies
3(13.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

15 of 18 finished

Non-Completion Rate

16.7%

3 ended early

Currently Active

2

trials recruiting

Total Trials

22

all time

Status Distribution
Active(2)
Completed(15)
Terminated(3)
Other(2)

Detailed Status

Completed15
Terminated2
unknown2
Recruiting1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
2
Success Rate
88.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (9.1%)
Phase 14 (18.2%)
Phase 211 (50.0%)
Phase 42 (9.1%)
N/A3 (13.6%)

Trials by Status

recruiting15%
terminated29%
completed1568%
unknown29%
withdrawn15%
active_not_recruiting15%

Recent Activity

2 active trials
Showing 5 of 22
completedphase_2

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

NCT03904498
active_not_recruitingphase_2

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

NCT05624528
completedearly_phase_1

Remediation of Impaired Self-Regulation in Patients With Mild TBI

NCT02260570
completedphase_2

Effects of Tolcapone on Frontotemporal Dementia

NCT00604591
terminatedphase_1

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

NCT02630043
View all 22 trials

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT03904498Phase 2

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

Completed
NCT05624528Phase 2

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

Active Not Recruiting
NCT02260570Early Phase 1

Remediation of Impaired Self-Regulation in Patients With Mild TBI

Completed
NCT00604591Phase 2

Effects of Tolcapone on Frontotemporal Dementia

Completed
NCT02630043Phase 1

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

Terminated
NCT06387771Phase 2

Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia

Recruiting
NCT02949934Phase 2

Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

Completed
NCT00927563Phase 2

Tolcapone Treatment of Pathological Gambling

Completed
NCT02929485Phase 4

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

Withdrawn
NCT02772978Not Applicable

Dopamine Responsivity in Gamblers

Completed
NCT02448654Not Applicable

Treatment for Nicotine Addiction in Women

Completed
NCT01158950Not Applicable

A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors

Completed
NCT02740582Phase 2

Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users

Completed
NCT03591757Early Phase 1

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

Completed
NCT03633591Phase 1

A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone

Completed
NCT00044083Phase 2

Clinical Trial of Tolcapone for Cognition in Schizophrenia

Terminated
NCT01202955Phase 2

Pilot Study of Tolcapone in Smokers

Completed
NCT02652598Phase 2

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

Unknown
NCT00033059Phase 1

Assessment of Potential Interactions Between Cocaine and Tolcapone - 1

Unknown
NCT02080715Phase 1

Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22